Pluri Inc PLUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PLUR is a good fit for your portfolio.
News
-
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
-
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
-
Pluri Inc. Announces 1-for-8 Reverse Share Split
-
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
-
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
-
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
-
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
-
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
Trading Information
- Previous Close Price
- $4.90
- Day Range
- $4.73–5.44
- 52-Week Range
- $3.45–8.56
- Bid/Ask
- $5.25 / $5.46
- Market Cap
- $28.00 Mil
- Volume/Avg
- 6,889 / 27,480
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 76.77
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company’s technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 134
- Website
- https://www.pluri-biotech.com
Valuation
|
Metric
|
PLUR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.34 |
Price/Sales | 76.77 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PLUR
|
|---|---|
Quick Ratio | 6.76 |
Current Ratio | 7.12 |
Interest Coverage | −28.46 |
Quick Ratio
PLUR
Profitability
|
Metric
|
PLUR
|
|---|---|
Return on Assets (Normalized) | −41.43% |
Return on Equity (Normalized) | −152.13% |
Return on Invested Capital (Normalized) | −46.47% |
Return on Assets
PLUR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tzvkclkgb | Yfw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rzjnffqmp | Kmjnhd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jzbzxhwd | Hnvxynn | $97.8 Bil | |
MRNA
| Moderna Inc | Bhvgtjjdf | Dld | $41.3 Bil | |
ARGX
| argenx SE ADR | Lzksrfby | Lmkt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kkfbvpps | Xybxp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hvzwklxs | Ymdmz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tdlrbnd | Vbmrwp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qkqlbmgnw | Cqcsybp | $12.5 Bil | |
INCY
| Incyte Corp | Nxrgydv | Msvsbyd | $11.6 Bil |